Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Blood lung cancer test company Cizzle Biotechnology reported narrower annual losses following a decline in expenses.
For the year ended 31 December 2020, pre-tax losses narrowed to £306,000 from £832,000 year-on-year as total administrative expenses fell to £306,000 from £832,000.
In 2020, the company was focused on completing the acquisition of Cizzle Biotechnology, which was wrapped up earlier in May, the company said.
'Cizzle Biotechnology's goal is to produce a test that can provide results quickly and accurately and which can lead to better outcomes for lung cancer patients,' it added.